Leonard Post Sells 5,000 Shares of CG Oncology (NASDAQ:CGON) Stock

CG Oncology, Inc. (NASDAQ:CGON) Director Leonard Post sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $65.00, for a total transaction of $325,000.00. Following the completion of the sale, the director directly owned 5,000 shares in the company, valued at approximately $325,000. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

CG Oncology Trading Up 4.5%

CGON opened at $68.72 on Thursday. The company has a 50 day moving average of $64.21 and a 200 day moving average of $57.70. The company has a market cap of $6.06 billion, a PE ratio of -29.49 and a beta of 0.31. CG Oncology, Inc. has a 12 month low of $23.65 and a 12 month high of $75.50.

CG Oncology (NASDAQ:CGON) last issued its earnings results on Friday, May 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.13). The business had revenue of $1.08 million for the quarter, compared to analyst estimates of $0.45 million. Research analysts forecast that CG Oncology, Inc. will post -2.89 earnings per share for the current fiscal year.

Hedge Funds Weigh In On CG Oncology

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CGON. NFSG Corp bought a new stake in shares of CG Oncology during the 1st quarter valued at about $34,000. Whittier Trust Co. of Nevada Inc. purchased a new stake in CG Oncology in the fourth quarter valued at approximately $27,000. Comerica Bank raised its position in shares of CG Oncology by 100.4% during the 4th quarter. Comerica Bank now owns 1,028 shares of the company’s stock valued at $43,000 after buying an additional 515 shares in the last quarter. Fifth Third Bancorp purchased a new stake in shares of CG Oncology during the 1st quarter valued at $74,000. Finally, KBC Group NV bought a new stake in shares of CG Oncology during the 1st quarter worth $78,000. 26.56% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. Wolfe Research started coverage on CG Oncology in a research note on Tuesday, May 19th. They set a “peer perform” rating on the stock. JPMorgan Chase & Co. raised their target price on CG Oncology from $91.00 to $96.00 and gave the stock an “overweight” rating in a research note on Monday, May 11th. Wedbush lifted their target price on CG Oncology from $77.00 to $80.00 and gave the company an “outperform” rating in a report on Monday, May 11th. Royal Bank Of Canada upped their price target on CG Oncology from $79.00 to $81.00 and gave the company an “outperform” rating in a research report on Monday, May 11th. Finally, Wall Street Zen downgraded shares of CG Oncology from a “hold” rating to a “sell” rating in a report on Saturday, April 25th. Eleven analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, CG Oncology currently has an average rating of “Moderate Buy” and a consensus price target of $81.73.

About CG Oncology

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.